William Berger

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691, USA
    Allergy Asthma Proc 27:214-23. 2006
  2. pmc New approaches to managing asthma: a US perspective
    William E Berger
    Allergy and Asthma Associates of Southern California Mission Viejo, CA, USA
    Ther Clin Risk Manag 4:363-79. 2008
  3. ncbi request reprint Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, Calif Electronic address
    J Allergy Clin Immunol Pract 2:179-85. 2014
  4. doi request reprint A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis
    William E Berger
    Allergy and Asthma Associates, Mission Viejo, CA 92691, USA
    Am J Rhinol Allergy 26:302-7. 2012
  5. pmc The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ)
    Michael Alexander
    Niagara Clinical Research, 5673 North Street, Niagara Falls, Ont L2G1J4, Canada
    Health Qual Life Outcomes 3:67. 2005
  6. ncbi request reprint The safety and efficacy of desloratadine for the management of allergic disease
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
    Drug Saf 28:1101-18. 2005
  7. ncbi request reprint Paediatric pulmonary drug delivery: considerations in asthma treatment
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, CA 92691 6410, USA
    Expert Opin Drug Deliv 2:965-80. 2005
  8. ncbi request reprint Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy
    William Berger
    Southern California Research, Mission Viejo, California, USA
    Ann Allergy Asthma Immunol 95:361-71. 2005
  9. doi request reprint The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children
    William E Berger
    Allergy and Asthma Associates of Southern California, 27800 Medical Center Road Number 244, Mission Viejo, CA 29691 6410, USA
    Allergy Asthma Proc 31:26-39. 2010
  10. ncbi request reprint Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis
    William Berger
    Southern California Research, Mission Viejo 92691, USA
    Ann Allergy Asthma Immunol 97:375-81. 2006

Detail Information

Publications63

  1. ncbi request reprint Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691, USA
    Allergy Asthma Proc 27:214-23. 2006
    ..All treatments were well tolerated. Desloratadine, 5 mg, and fexofenadine, 180 mg, provide comparable efficacy and tolerability in the treatment of SAR. Both treatments are significantly more effective than placebo...
  2. pmc New approaches to managing asthma: a US perspective
    William E Berger
    Allergy and Asthma Associates of Southern California Mission Viejo, CA, USA
    Ther Clin Risk Manag 4:363-79. 2008
    ..Considerable activity is taking place in asthma pharmacogenetics. This review provides an overview of these new approaches to managing asthma, including their present status and future potential...
  3. ncbi request reprint Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, Calif Electronic address
    J Allergy Clin Immunol Pract 2:179-85. 2014
    ..MP29-02 is a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate (FP) in an advanced delivery system for the treatment of seasonal allergic rhinitis...
  4. doi request reprint A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis
    William E Berger
    Allergy and Asthma Associates, Mission Viejo, CA 92691, USA
    Am J Rhinol Allergy 26:302-7. 2012
    ..A new, hydrofluoroalkane nasal aerosol solution formulation of ciclesonide (CIC-HFA) delivered via a metered dose inhaler is currently in clinical development for treatment of allergic rhinitis...
  5. pmc The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ)
    Michael Alexander
    Niagara Clinical Research, 5673 North Street, Niagara Falls, Ont L2G1J4, Canada
    Health Qual Life Outcomes 3:67. 2005
    ..The purpose of this study was to present the results of the psychometric validation of the EAPIQ...
  6. ncbi request reprint The safety and efficacy of desloratadine for the management of allergic disease
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
    Drug Saf 28:1101-18. 2005
    ..In addition, it has been shown to not interact with concomitantly administered drugs and food. Overall, current data indicate that desloratadine is a safe and effective treatment for allergic diseases...
  7. ncbi request reprint Paediatric pulmonary drug delivery: considerations in asthma treatment
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, CA 92691 6410, USA
    Expert Opin Drug Deliv 2:965-80. 2005
    ..Although age-based device recommendations have been made, the optimal choice for drug delivery is the one that the patient or caregiver prefers to use, can use correctly and is most likely to use consistently...
  8. ncbi request reprint Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy
    William Berger
    Southern California Research, Mission Viejo, California, USA
    Ann Allergy Asthma Immunol 95:361-71. 2005
    ..The Rhinoconjunctivitis Quality of Life Questionnaire and the Allergic Conjunctivitis Quality of Life Questionnaire quantify separate aspects of QoL...
  9. doi request reprint The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children
    William E Berger
    Allergy and Asthma Associates of Southern California, 27800 Medical Center Road Number 244, Mission Viejo, CA 29691 6410, USA
    Allergy Asthma Proc 31:26-39. 2010
    ..007). In this 26-week study of asthmatic children (6-11 years), safety profiles were similar and clinical benefits were greater with budesonide/formoterol than with budesonide...
  10. ncbi request reprint Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis
    William Berger
    Southern California Research, Mission Viejo 92691, USA
    Ann Allergy Asthma Immunol 97:375-81. 2006
    ....
  11. ncbi request reprint Budesonide inhalation suspension for the treatment of asthma in infants and children
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
    Drugs 65:1973-89. 2005
    ..However, available evidence suggests that growth effects are transient in children receiving budesonide and that these children eventually achieve full adult height...
  12. doi request reprint Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
    Allergy Asthma Proc 30:612-23. 2009
    ..In subjects 6 to <12 years of age, OLO was superior to vehicle in the treatment of SAR. In subjects 2 to <12 years of age, OLO had an overall low rate of AEs and low systemic exposure...
  13. ncbi request reprint Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody
    William E Berger
    Mission Viejo Medical Center, Mission Viejo, California 92691, USA
    Allergy Asthma Proc 27:S29-32. 2006
    ....
  14. ncbi request reprint The use of inhaled formoterol in the treatment of asthma
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
    Ann Allergy Asthma Immunol 97:24-33. 2006
    ..To discuss the clinical efficacy and safety of formoterol when used to relieve symptoms of asthma and prevent exercise-induced bronchoconstriction (EIB)...
  15. doi request reprint Treatment of acute bronchospasm in elderly patients
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
    Postgrad Med 118:34-7; discussion 38. 2005
    ..This paper presents results from clinical studies examining levalbuterol and racemic albuterol use among elderly patients who have asthma or COPD...
  16. ncbi request reprint Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma
    William E Berger
    Allergy and Asthma Associates, Mission Viejo, California 92691, USA
    Ann Allergy Asthma Immunol 97:672-80. 2006
    ..Mometasone furoate dry powder inhaler (DPI) has been shown to effectively treat asthma in children...
  17. ncbi request reprint Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease
    W E Berger
    Allergy and Asthma Associates of Southern California, 27800 Medical Asthma Associates, Suite 244, Mission Viejo, CA 92691, USA
    Respir Med 102:173-88. 2008
    ....
  18. ncbi request reprint Ciclesonide: a closer look at its systemic and oropharyngeal safety profile
    William E Berger
    Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, USA
    Curr Drug Saf 1:265-70. 2006
    ..The favorable safety profile of ciclesonide suggests a conferred benefit to asthma patients treated with this novel ICS...
  19. ncbi request reprint Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, USA
    Expert Opin Drug Metab Toxicol 5:91-102. 2009
    ....
  20. ncbi request reprint Aerosol devices and asthma therapy
    William Berger
    Allergy and Asthma Associates of Southern CA, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691 6410, USA
    Curr Drug Deliv 6:38-49. 2009
    ....
  21. ncbi request reprint Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, CA 92691, USA
    J Pediatr 146:91-5. 2005
    ..To compare the safety of budesonide inhalation suspension (BIS) with placebo in infants 6 to 12 months of age with mild to moderate persistent asthma or recurrent wheeze...
  22. ncbi request reprint Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion
    William E Berger
    Southern California Research, Mission Viejo, California 92691, USA
    Ann Allergy Asthma Immunol 89:485-91. 2002
    ..A nonsedating antihistamine that significantly decreases nasal congestion and improves symptoms of seasonal allergic asthma would be a significant advance in therapy...
  23. doi request reprint Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma
    William E Berger
    Allergy and Asthma Associates, 27800 Medical Center Road, Mission Viejo, CA 92691, USA
    Allergy Asthma Proc 31:49-59. 2010
    ..Once- or twice-daily BUD/FM showed better efficacy than BUD once daily or PBO; results generally were more favorable with twice-daily dosing compared with both once-daily dosing regimens, which had one-half the daily FM dose...
  24. ncbi request reprint Overview of allergic rhinitis
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
    Ann Allergy Asthma Immunol 90:7-12. 2003
    ..Half the patients with allergic rhinitis experience symptoms up to 4 months per year, whereas 20% are symptomatic more than 9 months of the year. This disease is often associated with asthma, sinusitis, and otitis media...
  25. ncbi request reprint Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma
    William E Berger
    Southern California Research, Mission Viejo, California 92691, USA
    Ann Allergy Asthma Immunol 90:583-91; quiz 591-2, 659. 2003
    ..To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma...
  26. ncbi request reprint Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis
    William E Berger
    Southern California Research, Mission Viejo, USA
    Otolaryngol Head Neck Surg 129:16-23. 2003
    ..Nasal symptom (discharge, stuffiness, itching, sneezing) severity was recorded twice daily; total nasal symptom score was calculated. Health-related quality of life was assessed by Rhinoconjunctivitis Quality of Life Questionnaire...
  27. ncbi request reprint Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids
    William E Berger
    Ann Allergy Asthma Immunol 89:393-9. 2002
    ..Studies have shown fluticasone propionate (FP) 100, 200, and 500 microg administered once daily to be effective in the treatment of asthma. The efficacy of a once daily regimen of FP 250 microg has not been evaluated previously...
  28. ncbi request reprint Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine
    William E Berger
    Southern California Research Center, Mission Viejo, California 92691, USA
    Ann Allergy Asthma Immunol 91:205-11. 2003
    ....
  29. ncbi request reprint Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma
    William Berger
    Mission Viejo Medical Center, Mission Viejo, California, USA
    Ann Allergy Asthma Immunol 91:182-8. 2003
    ..To evaluate the long-term effects of the anti-IgE antibody omalizumab in children with asthma...
  30. doi request reprint Mometasone furoate/formoterol in the treatment of persistent asthma
    William E Berger
    Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, CA, USA
    Expert Rev Respir Med 5:739-46. 2011
    ..Clinical safety studies lasting up to 1 year have found that MF/F has a low incidence of local and systemic side effects...
  31. ncbi request reprint Allergic rhinitis in children
    W E Berger
    Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691, USA
    Curr Allergy Asthma Rep 1:498-505. 2001
    ....
  32. ncbi request reprint Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease
    William E Berger
    Southern California Research, Mission Viejo 92691, USA
    Ann Allergy Asthma Immunol 88:152-60; quiz 161-2, 208. 2002
    ..To anticipate the likely effects (efficacy and safety) in clinical use in patients with allergic asthma and with allergic rhinitis. To characterize the types of patients who might benefit from this therapy...
  33. doi request reprint Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691 6410, USA
    J Asthma 47:447-59. 2010
    ..The objective was to review efficacy, safety, and pharmacogenetic data on budesonide/formoterol pMDI in the treatment of persistent asthma...
  34. ncbi request reprint Allergic rhinitis in children : diagnosis and management strategies
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, California, USA
    Paediatr Drugs 6:233-50. 2004
    ....
  35. ncbi request reprint Once-daily olopatadine ophthalmic solution 0.2% in the treatment of allergic conjunctivitis and rhinoconjunctivitis
    William E Berger
    Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, CA, USA Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, CA 92691, USA
    Expert Rev Pharmacoecon Outcomes Res 7:221-6. 2007
    ..This review article will summarize literature reports on the 0.2% formulation of olopatadine from the standpoint of efficacy, safety, total treatment costs, therapeutic outcomes, patient compliance and effect on quality of life...
  36. ncbi request reprint One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma
    George Bensch
    Georgetown Place, Stockton, California, USA
    Ann Allergy Asthma Immunol 89:180-90. 2002
    ..The long-term efficacy and safety of formoterol dry powder capsules for inhalation in pediatric asthma have not previously been evaluated...
  37. doi request reprint Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis
    Eli Meltzer
    Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA
    Int Arch Allergy Immunol 161:369-77. 2013
    ....
  38. ncbi request reprint Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, CA, USA
    Curr Med Res Opin 22:1217-26. 2006
    ..To evaluate the efficacy and safety of levalbuterol metered dose inhaler (MDI) in children aged 4-11 years (n = 173)...
  39. doi request reprint Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis
    Robert A Nathan
    Allergy and Asthma Associates, PC, Colorado Springs, Colorado 80907, USA
    Ann Allergy Asthma Immunol 100:497-505. 2008
    ..Intranasal corticosteroids are recommended as first-line therapy for the treatment of allergic rhinitis. Fluticasone furoate is a novel enhanced-affinity glucocorticoid for the treatment of allergic rhinitis...
  40. ncbi request reprint A patient satisfaction survey comparing levalbuterol with racemic albuterol in children
    William E Berger
    Southern California Research, Mission Viejo, California 92691, USA
    Allergy Asthma Proc 25:437-44. 2004
    ..This study supports the conclusion that the majority of caregivers of children with asthma who have experience with both levalbuterol and racemic albuterol prefer levalbuterol over racemic albuterol...
  41. doi request reprint Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California, USA
    Allergy Asthma Proc 30:304-14. 2009
    ..In this study, CIC80 b.i.d. improved disease control in subjects with mild-to-moderate persistent asthma not using an ICS and provided greater improvements than CIC160 q.d...
  42. ncbi request reprint Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance
    William E Berger
    Allergy and Asthma Associates, 27800 Medical Center Road, Suite 244, Mission Viejo, California 92691, USA
    Expert Opin Drug Deliv 4:689-701. 2007
    ..Findings suggest that the FF system should aid in improving attitudes to the use of intranasal corticosteroids amongst physicians and patients...
  43. doi request reprint Current options in the treatment of acute bronchospasm
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
    Postgrad Med 118:18-26. 2005
    ..Better control allows for better patient health, reduced number of physician and emergency department visits, and reduced health care costs...
  44. doi request reprint Asthma and COPD: definitions, epidemiology, and treatment guidelines
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
    Postgrad Med 118:2-8. 2005
    ..Prevalence of asthma may be leveling off. Prevalence of COPD is increasing, especially in women. Although several therapies are available, many patients do not seek treatment until COPD is moderately advanced...
  45. doi request reprint Acute bronchospasm from the patient's perspective
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California, Irvine, USA
    Postgrad Med 118:44-7; discussion 48. 2005
    ..These research studies point out that a very real "communications gap" exists between physicians and patients when examined from the patient's perspective...
  46. ncbi request reprint Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis
    William E Berger
    Department of Pediatrics, Division of Allergy and Immunology, University of California, Irvine, 92691, USA
    Ann Pharmacother 39:1984-9. 2005
    ..A recent survey estimated that 85% of patients with allergic rhinitis experience nasal congestion. This symptom considerably impacts quality of life...
  47. ncbi request reprint The use of inhaled corticosteroids for persistent asthma in infants and young children
    William E Berger
    Allergy and Asthma Associates of Southern California, Mission Viejo, California 92691, USA
    Ann Allergy Asthma Immunol 92:387-399; quiz 399-402, 463. 2004
    ..To review pediatric trials of inhaled corticosteroid (ICS) therapy and summarize data on the pediatric use of devices to facilitate delivery of ICSs...
  48. ncbi request reprint What is new in antiimmunoglobulin E asthma therapy
    William E Berger
    Allergy and Asthma Associates, Mission Viejo Medical Center, Mission Viejo, California 92691, USA
    Allergy Asthma Proc 26:428-34. 2005
    ....
  49. ncbi request reprint The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes
    William E Berger
    American College of Allergy, Asthma, and Immunology, Mission Viejo, California, USA
    Ann Allergy Asthma Immunol 93:538-45. 2004
    ..The Health Plan Employer Data and Information Set (HEDIS) measures are used extensively to measure quality of care...
  50. pmc Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder
    William Berger
    Department of Psychiatry, University of California, San Francisco, CA, USA
    Prog Neuropsychopharmacol Biol Psychiatry 34:1279-84. 2010
    ..Some studies have found that antidepressants increase serum brain-derived neurotrophic factor (BDNF) levels in patients with major depression and the expression of BDNF mRNA in limbic structures of rats...
  51. ncbi request reprint Access to allergy care: implications for quality healthcare and public safety
    William E Berger
    Southern California Research, Mission Viejo, CA, USA
    Manag Care Q 11:8-11. 2003
    ..Any action to reduce or limit coverage will not only diminish the quality of medical care for allergy patients but have significant health and safety implications for the general public...
  52. ncbi request reprint Pediatric allergic rhinitis: antihistamine selection
    William E Berger
    Allergy Asthma Associates, Mission Viejo, California 92691, USA
    Clin Pediatr (Phila) 44:655-64. 2005
  53. ncbi request reprint Judicious antibiotic use and intranasal corticosteroids in acute rhinosinusitis
    Catherine Butkus Small
    Division of Infectious Diseases, Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla 10595, USA
    Am J Med 120:289-94. 2007
    ..The use of intranasal corticosteroids in acute rhinosinusitis therefore might reduce the inappropriate use of antimicrobial therapy in acute rhinosinusitis...
  54. ncbi request reprint Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma
    Carlos E Baena-Cagnani
    Department of Paediatrics, Infantile Hospital, Santa Rosa, Cordoba, Argentina
    Int Arch Allergy Immunol 130:307-13. 2003
    ..Asthma and seasonal allergic rhinitis (SAR) are recognized as manifestations of a single airway disease. Desloratadine has demonstrated efficacy in treating SAR symptoms, including nasal obstruction...
  55. ncbi request reprint Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine
    Craig F LaForce
    Carolina Allergy and Asthma Consultants, Raleigh, North Carolina 27607, USA
    Ann Allergy Asthma Immunol 93:154-9. 2004
    ..Currently available oral second-generation antihistamines do not provide adequate symptom relief for many allergy patients...
  56. ncbi request reprint The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis
    George Philip
    Merck Research Laboratories, Rahway, NJ, USA
    Curr Med Res Opin 20:1549-58. 2004
    ..The objective of this study was to evaluate montelukast 10 mg daily as treatment for allergic rhinitis in patients with symptomatic allergic rhinitis and active asthma during the allergy season...
  57. ncbi request reprint Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model
    Miguel Brodsky
    Opthalmology Department, Israelita Medical Hospital, Buenos Aires, Argentina
    Eye Contact Lens 29:113-6. 2003
    ..The purpose of this study was to evaluate the comfort of olopatadine used for contact lens wearers in the conjunctival allergen-challenge (CAC) model...
  58. ncbi request reprint Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis
    Eli O Meltzer
    Allergy and Asthma Medical Group and Research Center, San Diego, California 92123, USA
    Ann Allergy Asthma Immunol 95:600-6. 2005
    ..A nasal spray containing the antiallergy agent olopatadine hydrochloride is being developed for the treatment of seasonal allergic rhinitis (SAR)...
  59. ncbi request reprint Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma
    David S Pearlman
    Colorado Allergy and Asthma Centers, PC, Denver 80230, USA
    J Allergy Clin Immunol 116:1206-12. 2005
    ..Inhaled corticosteroids are recommended as first-line therapy for persistent asthma...
  60. ncbi request reprint Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge
    Bob Q Lanier
    Fort Worth Allergy Asthma Association, Texas 76132, USA
    Clin Ther 24:1161-74. 2002
    ..It has not yet been determined whether a topical or systemic agent is more effective for the latter purpose...
  61. ncbi request reprint The variability of asthma
    Kevin R Murphy
    Midwest Children s Chest Physicians, Omaha, NE 68130, USA
    Curr Med Res Opin 21:1519-26. 2005
    ..Awareness of episodic changes in asthma severity, with subsequent tailored adjustment in guideline-based ICS therapy, should enable optimal control of asthma with minimal medication requirements...
  62. ncbi request reprint Direct and indirect costs of asthma to an employer
    Howard G Birnbaum
    Analysis Group Economics, Cambridge, MA 02138, USA
    J Allergy Clin Immunol 109:264-70. 2002
    ..Asthma is a chronic inflammatory condition of the airways that has a significant effect on the use of health care resources...
  63. ncbi request reprint Symptom severity assessment of allergic rhinitis: part 1
    Sheldon L Spector
    Ann Allergy Asthma Immunol 91:105-14. 2003